Considering the upregulation of CMA established in almost all solid cancer types assessed to-date (Arias and Cuervo, 2020; Dong et al, 2025; Ichikawa et al, 2020; Kon et al, 2011) and our observed correlation of increased NCoR1/RARα with increasing CMA score across a diverse panel of cancer types, we predict that our small molecule targeting strategy inhibiting NCoR1/RARα interaction with CIM7 or an optimized derivative may have translational value in a variety of cancers, as illustrated through the course of our study in NSCLC. This evidence concerns the gene RARA and non-small cell lung carcinoma.